source
- AstraZeneca and Ionis report failure of eplontersen in ATTR-CM trialAstraZeneca and Ionis said their nucleic‑acid drug eplontersen did not meet the primary goal in a large study of patients with transthyretin‑mediated amyloid cardiomyopathy (ATTR‑CM). Over a 140‑we…
- AstraZeneca and Ionis see pivotal trial miss for ATTR-CM drug WainuaAstraZeneca announced that its experimental therapy Wainua, developed with Ionis, failed to meet primary endpoints in a pivotal study for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). T…